DJIA 17,154.57 123.43 0.72%
NASDAQ 4,549.36 30.46 0.67%
S&P 500 2,002.27 18.14 0.91%
market minute promo

AbbVie Inc. (NYSE: ABBV)

58.60 0.67 (1.16%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

ABBV $58.60 1.16%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $57.63
Previous Close $57.93
Daily Range $57.46 - $58.50
52-Week Range $44.02 - $58.77
Market Cap $93.3B
P/E Ratio 22.45
Dividend (Yield) $1.68 (2.9%)
Ex-Dividend Date
Dividend Pay Date
07/11/14
08/15/14
Volume 4,770,815
Average Daily Volume 10,114,599
Current FY EPS $3.13

Sector

Industry

AbbVie Inc. (ABBV) Description

AbbVie Inc. Website: http://www.abbvie.com/

News & Commentary Rss Feed

After Apple: Tech's Takeover of Healthcare Officially Begins

Ebola is spreading, new diabetes and obesity drugs, and Apple and Google move into healthcare, because this is where the money is.

Buy The Dip In Gilead: Why A Decrease In Quarterly Sovaldi Revenue Is Expected

If Achillion's Hep C Nucleotide Isn't Best In Class, The Stock Is Worth Low Single Digits

Biogen/AbbVie Report Positive Data on MS Drug Zinbryta - Analyst Blog

Abbott Labs Presents Positive One-Year Data on Absorb - Analyst Blog

Abbott Labs Presents Positive One-Year Data on Absorb - Analyst Blog

Notable ETF Outflow Detected - SSO, MMM, ABT, ABBV

U.S. Hepatitis Problem to Continue Driving These 4 Top Stocks

AbbVie's Humira Positive in Phase III Skin Disease Study - Analyst Blog

Abbott Labs (ABT) to Repurchase Shares for $3B - Analyst Blog

4 Reasons Sangamo Biosciences Is Positioned For A Run-Up

Incyte Pharmaceutical: Top Idea For 2H14 With 2 Free Call Options Driving M&A Valuation To $93, Gile

Incyte Pharmaceutical: Top Idea For 2H14 With 2 Free Call Options Driving M&A Valuation To $93, Gilead Most Likely Suitor

See More ABBV News...